@naomicampbelpamanderson's GLP-1 claims need context

What did @naomicampbelpamanderson actually say?

The creator said, directly and without elaboration: "Oh, good luck with your anorexia. You're eating disorders. Eating disorders." That is the entire content of this video. There is no medical context, no qualification, and no apparent irony. The implication is that people using GLP-1 medications, or people losing weight on them, are simply anorexic. It reads as mockery, not commentary.

This is worth examining seriously, because the conflation of GLP-1-assisted weight loss with eating disorders is a real conversation happening in clinical settings, not just on TikTok. The creator stumbled into a legitimate medical debate, but handled it with about as much nuance as a shouted insult.

Does the science back this up?

No. GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite through a specific neurological mechanism. That mechanism is not anorexia. Anorexia nervosa is a psychiatric diagnosis defined by distorted body image, fear of weight gain, and self-starvation. These are categorically different things.

Semaglutide works by mimicking the GLP-1 hormone, which slows gastric emptying and signals satiety to the hypothalamus. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed an average 14.9% body weight reduction over 68 weeks, driven by reduced caloric intake as a side effect of the drug, not psychological restriction. The drug does the work. Calling that an eating disorder is like calling beta-blockers a panic disorder.

There is a legitimate clinical concern that GLP-1 medications could mask or worsen disordered eating in people with pre-existing eating disorders, and researchers like Giel et al. (2023, Nutrients) have flagged this as an area requiring more study. But that nuance is miles away from what this creator said.

What did they get wrong (or right)?

They got almost everything wrong, but the buried concern is not completely baseless. Clinicians are genuinely debating whether GLP-1 medications are appropriate for patients with a history of restrictive eating disorders. The mechanism that suppresses hunger could theoretically reinforce restriction in someone already psychologically inclined to restrict. That is a real conversation.

But the creator did not make that argument. They mocked people taking the medication. There is a difference between "we should screen patients for eating disorder history before prescribing" and "good luck with your anorexia." One is clinical caution. The other is stigma wearing a lab coat it does not own.

The creator also implies that GLP-1-induced appetite reduction is equivalent to an eating disorder. It is not. Pharmacologically suppressed appetite is a drug effect, not a psychiatric condition. Framing it otherwise misrepresents both the medication and the millions of people living with actual eating disorders.

What should you actually know?

If you are on a GLP-1 medication and eating less, that is the mechanism working, not a disorder. You should still eat enough protein and micronutrients to support muscle retention, which is a documented concern in GLP-1 trials. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) for tirzepatide noted that lean mass loss is a real side effect worth monitoring with a prescriber.

If you have a history of an eating disorder, that is a conversation to have with your doctor before starting any appetite-suppressing medication. Not because the medication causes anorexia, but because clinical screening matters. People with active eating disorders were excluded from major GLP-1 trials, which means we have limited data on that population specifically.

TikTok mockery dressed up as health commentary causes real harm. It stigmatizes both GLP-1 users and people living with eating disorders by conflating two things that are not the same. A regulated telehealth provider should be the correction to that noise, not another voice amplifying it.